Development of an Atlas of Respiratory Host-microbiome Interactions in Healthy Volunteers

Last updated: May 13, 2025
Sponsor: Nantes University Hospital
Overall Status: Active - Recruiting

Phase

N/A

Condition

N/A

Treatment

Voluntary

Clinical Study ID

NCT06518161
RC24_0007
  • Ages 18-70
  • All Genders
  • Accepts Healthy Volunteers

Study Summary

The role of the pulmonary microbiome in the pathophysiology of lung disease is becoming increasingly well understood. Studies on murine models have highlighted the immunomodulatory and antibacterial activity of certain commensal bacteria, such as S. mitis, and have led to an understanding of their potential therapeutic impact. The investigators will therefore couple their analyses of the respiratory microbiome with an in-depth analysis of mucosal immunity. In particular, they will characterize immune cell types and frequencies using high-dimensional (spectral) flow cytometry and single cell RNA-sequencing. Finally, they will study the mediators exchanged between the microbiome and the host using proteomic and metabolomic analyses of respiratory fluids.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Male or female.

  • Age from 18 to 70.

  • Indication for scheduled general anesthesia with orotracheal intubation fornon-thoracic, non-carcinological, non-septic surgical procedures such as prosthesis (knee or hip), spinal surgery, digestive hernia surgery, gall bladder surgery,maxillofacial surgery (non-exhaustive list).

  • Membership of a social security scheme or beneficiary of such a scheme.

  • Written informed consent.

Exclusion

Exclusion Criteria:

  • Persons under guardianship or trusteeship.

  • Pregnant or breast-feeding woman.

  • Antibiotic treatment received within 28 days prior to surgery, regardless of thesite of infection.

  • Acute respiratory pathology within the last 28 days (pneumothorax, bronchitis orpneumonia including Covid).

  • History of chronic respiratory disease (asthma, chronic obstructive pulmonarydisease, emphysema, lung cancer, cystic fibrosis, etc.).

  • Immunosuppression (cancer active or within the last 5 years, HIV, radio-chemotherapywithin the last year, organ transplant).

  • Chronic inflammatory disease (digestive, osteoarticular, neurological or cutaneous)requiring or having required specific treatment in the last 12 months.

  • Type I or II diabetes.

  • Steroid treatment within the last 30 days (regardless of dose or duration).

Study Design

Total Participants: 75
Treatment Group(s): 1
Primary Treatment: Voluntary
Phase:
Study Start date:
January 03, 2025
Estimated Completion Date:
July 01, 2027

Connect with a study center

  • CHU de Nantes

    Nantes,
    France

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.